Home › Funds › Rubric Capital Management LP › ARQT
Rubric Capital Management LP position in ARQT
ARCUTIS BIOTHERAPEUTICS INC · Health Care
Rubric Capital Management LP reported holding 8,271,577 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$216.9M, representing 2.00% of its reported portfolio and ranking #13 among its reported holdings. Rubric Capital Management LP has disclosed ARQT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Rubric Capital Management LP's ARQT position evolved
Rubric Capital Management LP first disclosed a stake in ARQT in Q3 2023 at 5,034,530 shares (US$26.7M). The position peaked in Q4 2025 at 8,271,577 shares, worth US$240.2M. Across 12 filings, Rubric Capital Management LP increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 8,271,577 shares valued at US$216.9M. Notable position changes include a 32% increase in Q4 2023 (shares rose 207% over the following quarter), a 31% increase in Q2 2024 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.03M | $26.73M | New |
| Q4 2023 | 6.64M | $21.46M | Add |
| Q1 2024 | 7.51M | $74.42M | Add |
| Q2 2024 | 9.82M | $91.30M | Add |
| Q3 2024 | 10.97M | $101.99M | Add |
| Q4 2024 | 10.97M | $152.77M | Hold |
| Q1 2025 | 10.97M | $171.52M | Hold |
| Q2 2025 | 10.75M | $150.71M | Reduce |
| Q3 2025 | 10.75M | $202.63M | Hold |
| Q4 2025 | 8.27M | $240.21M | Reduce |
| Q1 2026 | 8.27M | $194.88M | Hold |
| Q2 2026 | 8.27M | $216.88M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARQT and 13F data
ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), ORBIMED ADVISORS LLC (US$53.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARQT
- MONTANOVA CAPITAL, LLC 12.44M sh · $326.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.87M sh · $258.91M · Q2 2026
- ORBIMED ADVISORS LLC 2.04M sh · $53.54M · Q2 2026
- OBERWEIS ASSET MANAGEMENT INC/ 1.37M sh · $36.00M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.27M sh · $33.18M · Q2 2026
- Jones Hill Capital LP 1.09M sh · $28.57M · Q2 2026
- FISHMAN JAY A LTD/MI 595.00K sh · $15.60M · Q2 2026
More on Rubric Capital Management LP
FAQ
How long has Rubric Capital Management LP held ARQT?
Rubric Capital Management LP has disclosed ARQT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Rubric Capital Management LP's current position in ARQT?
As of Q2 2026, Rubric Capital Management LP holds 8.27M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $216.88M, representing 2.00% of its reported portfolio and ranking #13.
Has Rubric Capital Management LP been buying or selling ARQT?
In the latest 13F filing (Q2 2026), Rubric Capital Management LP held unchanged its position in ARQT. The position peaked in Q4 2025 at 8.27M shares.
Which other funds hold ARQT?
Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., ORBIMED ADVISORS LLC, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.